Metformin Versus Myo-inositol in the Management of Polycystic Ovarian Disease: A Comparative Study

Starting soon · Phase 1

Conditions studied: Polycystic Ovarian Syndrome (PCOS)

In brief

In polycystic ovary syndrome (PCOS), changes in physical appearance i.e. weight gain, hirsutism, menstrual disturbances and infertility result in reduced quality-of-life. PCOS is one of the most common endocrine disorders affecting about 4% to 8% of women of reproductive age. Diagnosis is primarily clinical with Rotterdam criteria being the most commonly followed criteria, which require the presence of two out of the three criteria including oligo and/or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries on ultrasound. The objective of this study is to compare the outcome of Metformin versus Myo-inositol in the management of polycystic ovarian disease.

Key facts

Study ID

NCT07459595

Run by

Fatima Tariq

People needed

60

Starts

2026-05-01

Expected to finish

2026-07-31

Last updated by the study team

2026-03-10

Who can join

Age: 16 and older, up to 45. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Married or unmarried
• Diagnosed with PCOS (females presenting with compliant of irregular cycle for >3 months, with hirsutism, acne, presence of polycystic ovaries detected on ultrasound ).

You may not qualify if…

• Females already taken or taking PCOS treatment (on medical record)
• Females already enrolled in another trial program
• Females already taking trial drugs
• Females with chronic diabetes (BSR>200 mg/dl), hypertension (BP≥140/90mmHg)
• Females with PCOS along with gestational sac (on ultrasound)
• Females allergic to any content of trial drugs (on history)

Where it is running

• CMH Gujranwala — Guiranwala, Punjab Province, Pakistan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.